Using cfDNA and ctDNA as oncologic markers: a path to clinical validation
J Dao, PJ Conway, B Subramani… - International journal of …, 2023 - mdpi.com
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …
[HTML][HTML] Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis
L Vidal, E Pando, L Blanco, C Fabregat-Franco… - Cancer Treatment …, 2023 - Elsevier
Background It has been hypothesised that manipulation during surgery releases tumoral
components into circulation. We investigate the effect of surgery on plasma-borne DNA …
components into circulation. We investigate the effect of surgery on plasma-borne DNA …
[HTML][HTML] The PANcreatic Disease ReseArch (PANDoRA) consortium: ten years' experience of association studies to understand the genetic architecture of pancreatic …
D Campa, M Gentiluomo, A Stein, MN Aoki… - Critical Reviews in …, 2023 - Elsevier
Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of
risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of …
risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of …
The role of cell-free DNA in cancer treatment decision making
A Telekes, A Horváth - Cancers, 2022 - mdpi.com
Simple Summary The aim of this review is to evaluate the present status of the use of cell-
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …
free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an …
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
C Nitschke, B Markmann, P Walter… - Clinical …, 2023 - academic.oup.com
Background KRAS circulating tumor DNA (ctDNA) has shown biomarker potential for
pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet …
pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet …
Diagnostic and therapeutic potential of circulating-free DNA and cell-free RNA in cancer management
Over time, molecular biology and genomics techniques have been developed to speed up
the early diagnosis and clinical management of cancer. These therapies are often most …
the early diagnosis and clinical management of cancer. These therapies are often most …
Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients
C Maulat, C Canivet, B Cabarrou, A Pradines… - Scientific Reports, 2024 - nature.com
In PDAC patients, ctDNA detection's prognostic significance needs validation especially in
resected patients. This study investigated ctDNA kinetics in portal and peripheral blood …
resected patients. This study investigated ctDNA kinetics in portal and peripheral blood …
Is cell-free DNA testing in pancreatic ductal adenocarcinoma ready for prime time?
A Sheel, S Addison, SP Nuguru, A Manne - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic cancer is a deadly cancer with limited treatment options. It is
often detected in most people at stages where cure is not possible. There is no good test to …
often detected in most people at stages where cure is not possible. There is no good test to …
Diagnosis of pancreatic cancer using miRNA30e biosensor
N Sharma, S Srivastava - Interdisciplinary Sciences: Computational Life …, 2022 - Springer
This work describes miRNA-based electrochemical biosensor for detection of miRNA30e, a
pancreatic cancer biomarker. The screen-printed gold electrode was functionalized using …
pancreatic cancer biomarker. The screen-printed gold electrode was functionalized using …
Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study
HS Lee, EH Jung, H Shin, CS Park, SB Park… - Frontiers in …, 2023 - frontiersin.org
Objective Early chemoresistance and tumor mass progression are associated with poor
prognosis in pancreatic ductal adenocarcinoma (PDAC). Circulating tumor cells (CTCs) …
prognosis in pancreatic ductal adenocarcinoma (PDAC). Circulating tumor cells (CTCs) …